Rocket Pharmaceuticals
RCKT
225 hedge funds and large institutions have $1.38B invested in Rocket Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 97 increasing their positions, 44 reducing their positions, and 25 closing their positions.
136% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 25
120% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 44
18% more funds holding
Funds holding: 191 → 225 (+34)
1.25% more ownership
Funds ownership: 101.86% → 103.11% (+1.3%)
9% less call options, than puts
Call options by funds: $2.08M | Put options by funds: $2.28M
19% less capital invested
Capital invested by funds: $1.71B → $1.38B (-$331M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$41.4M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$38.6M |
| 3 |
Janus Henderson Group
London,
|
+$31.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$29.7M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$22.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$16.2M |
| 2 |
Millennium Management
New York
|
-$13M |
| 3 |
BAMCO Inc
New York
|
-$12.2M |
| 4 |
FTM
First Turn Management
Del Mar,
California
|
-$11.5M |
| 5 |
PA
Perceptive Advisors
New York
|
-$8.33M |
RCKT Hedge Fund Activity: Q4 2024 in Review
225 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2024, worth a combined $1.38B — down 19% from $1.71B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new RCKT positions and 25 closed out — a net gain of 34 holders — while 97 added to existing stakes and 44 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $41.4M. The largest seller was Franklin Resources, cutting an estimated $16.2M.
- 225 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2024, up from 191 in Q3 2024.
- Funds reported $1.38B of Rocket Pharmaceuticals stock for Q4 2024, down 19% quarter-over-quarter.
- 59 funds opened new Rocket Pharmaceuticals positions in Q4 2024 and 25 closed out, a net change of +34 holders.
- The largest Rocket Pharmaceuticals buyer in Q4 2024 was Wellington Management Group, an estimated $41.4M added.
- The largest Rocket Pharmaceuticals seller in Q4 2024 was Franklin Resources, an estimated $16.2M sold.
Based on aggregated 13F filings for Q4 2024.